<DOC>
	<DOCNO>NCT01084265</DOCNO>
	<brief_summary>This prospective , open , non-comparative study evaluate safety efficacy recombinant human luteinizing hormone ( rhLH , Luveris ) administer subcutaneously ( s.c. ) follicular development ovulation induction 31 Chinese female subject hypogonadotropic hypogonadism .</brief_summary>
	<brief_title>A Study Using Recombinant Human Luteinizing Hormone ( r-hLH , Luveris® ) Treatment Chinese Women With Hypogonadotropic Hypogonadism</brief_title>
	<detailed_description>The objective prospective , open , non-comparative study ass safety efficacy rhLH ( Luveris ) administer subcutaneously follicular development ovulation induction Chinese female subject hypogonadotropic hypogonadism . The study organize outpatient basis involve single cycle treatment . Prior entry study , diagnosis hypogonadotropic hypogonadism confirm history , presence absence specific clinical feature measure serum gonadotropin level . Once subject sign informed consent form satisfy eligibility criterion , subject receive combination daily injection recombinant human follicle-stimulating hormone ( rhFSH ) 150 international unit ( IU ) plus rhLH 75 IU . After adequate follicular response , ovulation induction trigger injection 10,000 IU human chorionic gonadotropin ( hCG ) . Luteal phase function assess serum progesterone level determination .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<criteria>Be premenopausal , 18 39 year age Have clinical history hypogonadotropic hypogonadism , laboratory test result comply diagnosis hypogonadotropic hypogonadism screen procedure Have discontinue gonadotropin , gonadotropinreleasing hormone ( GnRH ) ( gonadotropin naïve ) , estrogen progesterone replacement therapy least one month screen procedure Have negative progestin challenge test perform screen Have follow hormonal value centrally analyze fast blood sample , drawn within 6 month initiation treatment : Follicular stimulate hormone ( FSH ) : &lt; 5 international units/liter ( IU/L ) Luteinizing hormone ( LH ) : &lt; 1.2 IU/L Oestradiol ( E2 ) : &lt; 60 picogram/milliliter ( pg/mL ) ( &lt; 220 picomolar/liter [ pmol/L ] ) Prolactin ( PRL ) : &lt; 44.3 nanogram/milliliter ( ng/mL ) ( &lt; 1040 milliinternational units/liter [ mIU/L ] ) Thyrotrophinstimulating hormone ( TSH ) : &lt; 6.5 microinternational unit ( uIU/mL ) Free Thyroxine ( T4 ) : 0.81.8 nanogram/deciliter ( ng/dL ) ( 1124 pmol/L ) Triiodothyronine ( T3 ) : &lt; 1.0 ng/mL ( &lt; 3.5 nanomolar/liter [ nmol/L ] ) Have endovaginal pelvic ultrasound scan showing ( ) ovarian tumor cyst &lt; 2 centimeter ( cm ) ; ( ii ) clinically significant uterine abnormality , ( iii ) &lt; 13 mm small follicle ( mean diameter &lt; 10 mm ) large section ovary Have normal cervical pap smear within 6 month initial visit Have body mass index ( BMI ) 18.4 31.4 kilogram/meter square ( kg/m^2 ) Be willing able comply protocol duration study Have give write informed consent prior study related procedure Ongoing pregnancy Any chronic systemic disease Hypersensitive study drug control drug History severe ovarian hyperstimulation syndrome Abnormal gynecological bleeding undetermined origin Previous current hormone dependent tumor Known active substance abuse eat disorder Known central nervous system ( CNS ) lesion : In case hypogonadotropic hypogonadism ( HH ) secondary CNS lesion treatment , subject eligible without consult Serono 's Medical Director Exercise program exceed 10 hour per week Currently undergo treatment psychotropic medication medication know interfere normal reproductive function ( example , neuroleptic , dopamine antagonist ) There abnormality , decide investigator , might produce effect absorption , distribution excretion investigational drug</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Hypogonadism</keyword>
	<keyword>Recombinant human follicle stimulate hormone ( r-hFSH )</keyword>
	<keyword>Recombinant leutinizing hormone ( r-hLH )</keyword>
</DOC>